Moderna, a trailblazer in vaccine development, announced on Wednesday that Blackstone’s life sciences sector will inject $750 million into the advancement of its influenza vaccines. This significant funding comes at a pivotal moment for Moderna as the company navigates the aftermath of diminished COVID-19